Drugs Made In America Acquisition (DMAA) Change in Cash (2025)

Drugs Made In America Acquisition's (DMAA) quarterly Change in Cash came in at $5420.0 in Q4 2025, up 5261.9% on a QoQ basis from -$105.0 in Q3 2025.

Drugs Made In America Acquisition (DMAA) Change in Cash (2025) Analysis & Trends

Drugs Made In America Acquisition (DMAA) has 1 years of Change in Cash data on file, last reported at $5420.0 in Q4 2025.

Quarterly Change in Cash changed N/A year-over-year to $5420.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4786.0 (changed N/A YoY) and the FY2025 annual result came in at $4786.0, up 254.26% from the prior year.
Change in Cash advanced to $5420.0 in Q4 2025, from -$105.0 in the prior quarter.
In the past five years, Change in Cash ranged from a high of $5420.0 in Q4 2025 to a low of -$428.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Cash (Qtr)
1	Oxley Bridge Acquisition	585.76 Mn	585.76 Mn	-	-162,173.00
2	Launch Two Acquisition	557.86 Mn	557.86 Mn	-	-109,362.00
3	Drugs Made In America Acquisition	507.00 Mn	507.00 Mn	-	-
4	Cantor Equity Partners IV	468.00 Mn	468.00 Mn	-	-
5	GP-Act III Acquisition	401.06 Mn	401.06 Mn	-	-
6	Aldel Financial	397.49 Mn	397.49 Mn	-	-81,520.00
7	Republic Digital Acquisition	389.25 Mn	388.51 Mn	-	-133,765.00
8	Gores Holdings X	385.06 Mn	384.87 Mn	-	-236,785.00
9	Agriculture & Natural Solutions Acquisition	377.29 Mn	377.04 Mn	-	-
10	Drugs Made In America Acquisition	215.82 Mn	215.82 Mn	-	-

Download Data